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Introduction
The use of natural health products (NHPs) is increasing
[1]. Reasons for the increased public use of NHPs vary
from individual involvement in health decisions to distrust
in medical organisations [2,3]. With increasing research in
complementary and alternative medicine (CAM) comes an
increase in public health awareness of social and safety
concerns [4,5]. This is particularly true in terminal dis-
eases, in which patients may seek out marketed cures and
treatments based on folklore [6].
Breast cancer patients might be particularly vulnerable to
the use of NHPs because women are large consumers of
them [7]. Several public health concerns arise about the
use of NHPs. The potential for drug interactions with
chemotherapy might reduce or exacerbate the effective-
ness of prescription drugs [8,9]. The potential for harm
increases when large doses of products are used chroni-
cally and when multiple NHPs are used simultaneously
[10]. Additionally, patients might delay or discontinue
orthodox treatment at the advice of a CAM practitioner
CAM = complementary and alternative medicine; NHPs = natural health products.
Breast Cancer Research    Vol 5 No 6 Mills et al.
Research article
Health food store recommendations: implications for breast
cancer patients
Edward Mills1,2, Edzard Ernst3, Rana Singh1, Cory Ross1 and Kumanan Wilson4
1Department of Research, Canadian College of Naturopathic Medicine, North York, Ontario, Canada
2University of Oxford, Oxford, UK
3Department of Complementary Medicine, University of Exeter, Exeter, UK
4Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Corresponding author: Edward Mills (e-mail: emills@ccnm.edu)
Received: 29 Apr 2003   Revisions requested: 17 Jun 2003   Revisions received: 20 Jun 2003   Accepted: 8 Jul 2003   Published: 7 Aug 2003
Breast Cancer Res 2003, 5:R170-R174 (DOI 10.1186/bcr636)
© 2003 Mills et al., licensee BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X). This is an Open Access article: verbatim
copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original
URL.
See related Commentary: http://breast-cancer-research.com/content/5/6/300
Abstract
Background: Many breast cancer patients use complementary
and alternative medicine (CAM). We aimed to determine what
advice health food store employees present to individuals
seeking treatment options for breast cancer.
Methods: Eight data gatherers asked employees of all retail
health food stores in a major Canadian city, what they
recommended for a patient with breast cancer. The data
gatherers inquired about product safety, potential drug
interactions, costs and efficacy. They also enquired about
employee training related to the products.
Results: Thirty-four stores were examined. A total of
33 different products were recommended, none of which are
supported by sufficient evidence of efficacy. The average cost
of the products they recommended was $58.09 (CAD)
(minimum $5.28, median $32.99, maximum $600) per month.
Twenty-three employees (68%) did not ask whether the patient
took prescription medications. Fifteen employees (44%)
recommended visiting a healthcare professional (naturopaths
(9), physicians (5), nutritionists (1)). Three employees (8.8%)
discussed potential adverse effects of the products. Eight
employees (23.5%) discussed the potential for drug
interactions. Two employees (5.9%) suggested a possible cure
with the products and one employee (2.9%) suggested
discontinuing Tamoxifen. Four employees (11.8%)
recommended lifestyle changes and three employees (8.8%)
recommended books for further reading on the products.
Conclusion: This study draws attention to the heterogeneity of
advice provided by natural health food stores to individuals
seeking treatments for breast cancer, and the safety and cost
implications of some of the products recommended. Physicians
should enquire carefully about the use of natural health food
products by patients with breast cancer. Regulators need to
consider regulations to protect vulnerable patients from incurring
significant costs in their purchasing of natural health food
products lacking evidence of benefit and of questionable safety.
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because the discussion of CAM use with physicians is
limited [11]. NHPs and CAM usage might also prove to be
an expensive treatment option for breast cancer patients.
Methods
We conducted a field study to determine what health food
store employees recommended to individuals seeking
treatments for breast cancer. We focused on identifying
what products were recommended and the cost of these
products. We also examined the education of these
employees and their knowledge of drug interactions and
adverse effects.
We identified all health food stores in a major Canadian
city through the local business pages and yellow pages of
telephone directories. Further stores were located through
word of mouth. In total, 34 stores met our inclusion criteria
of being a retail NHP sales outlet. We specifically excluded
Asian herbal stores because of language difficulties.
This study received ethical approval by the Canadian
College of Naturopathic Medicine Ethical Review Board
and approved with reference to Office for Protection from
Research Risks Regulations under section 46.116(d).
Procedure
Eight research assistants (six female, two male) of various
ages and appearances were recruited and trained to
portray customers (‘participants-as-observers’). The partici-
pants entered individually into assigned stores; they had
been informed to browse in the store until approached by
an employee. At this time the participants would declare
that their mother has breast cancer. The participants dis-
closed information on their mother’s condition, use of
chemotherapy (Tamoxifen) and physician visits, only if
asked. The participants would then ask what the employee
recommended for this condition. All participants followed a
structured, memorized, pretested questionnaire that asked
about product usage, dosage, cost, employee education
and product safety or potential for drug interactions. No
further information about the condition was divulged.
The data gatherers recorded which products were recom-
mended by natural health food store employees, along
with the recommended dose and price per product as well
as price per month. Data gatherers inquired about safety
issues and drug interactions with each recommended
product. Additionally, they inquired about where the
employee had obtained information on the recommended
products. They also noted whether the employees referred
them on to CAM specialists or recommended that they
consult further with a physician. Additional suggestions by
the employees were recorded.
Full notes on the encounters were recorded immediately
after leaving the store. All data were transcribed according
to the research questions. The research assistants specifi-
cally recorded the various products recommended, includ-
ing their costs and dosage. We summarised the data with
descriptive statistics. We have disclosed the results of our
audit to each health food store.
Results
Of the 34 stores that met our inclusion criteria, 27 recom-
mended NHPs; a total of 33 different products were rec-
ommended (see Table 1). The mean cost of product per
month was $58.09 (CAD) (minimum $5.28, median
$32.99, maximum $600). Twenty-three employees (68%)
did not ask whether the patient took prescription medica-
tions. Fifteen (44%) employees recommended visiting a
healthcare professional; these included: naturopaths (9),
physicians (5) and nutritionists (1). Health food store
employees relied on a variety of sources of information.
Twelve employees (35%) received their information from
books, 5 (15%) from a supplier, 3 (9%) had a formal edu-
cation in CAM, 2 (6%) had in-store training and 12 (35%)
did not disclose their sources of information.
Potential adverse effects of recommended products were
discussed by three employees (8.8%). The potential for
drug interactions was discussed by eight employees
(23.5%). Two (5.9%) suggested that the products might
offer the potential for cure. One employee (2.9%) sug-
gested discontinuing Tamoxifen. Four employees (11.8%)
suggested lifestyle changes and three (8.8%) recom-
mended books for further reading on the products.
Discussion
Several important messages emerge from this analysis of
advice provided to breast cancer patients in health food
stores. These stores are recommending a variety of prod-
ucts, none of which is supported by evidence of benefit. In
many instances the stores do not discuss the potential for
adverse effects of these products or the possibility of drug
interactions. In addition, in at least one instance in this
study, an employee recommended that a conventional
medical therapy (Tamoxifen) be discontinued. The findings
of our study are consistent with previous reports on the
practice of natural health food stores [12–19]. Other
studies examining advice provided about CAM on the
Internet, another readily available source, find that this
advice can also be misleading and could seriously harm
consumers [20].
All these findings highlight the importance of physicians’
awareness of the possibility that their breast cancer
patients are seeking advice and treatment from alternative
medical sources such as natural health food stores.
Patients might not disclose this information to their tradi-
tional health care providers. However, the advice they
seek could have a negative effect on their response to
medical treatment and be the source of unexplained reac-Breast Cancer Research    Vol 5 No 6 Mills et al.
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tions [21]. This study also highlights the vulnerability of
patients with breast cancer to potentially misleading infor-
mation from health food employees. Advice presented by
health food employees was authoritative and could be
misconstrued by patients as evidence-based, particularly
when books are consulted or literature is provided on the
products. This was illustrated by the two employees who
suggested that their recommended products could cure
the patient of cancer. It is important to note that, with the
exception of small trials examining the efficacy of coen-
zyme Q10 [22,23] and vitamin C [24], there is no evidence
from clinical trials to support the use of the recommended
products by patients with breast cancer [25–27]. The dis-
trust of conventional medical treatments by individuals
Table 1
Frequency, dosage and monthly cost of products recommended by 34 natural health food store employees
No. of stores Cost for a monthly
Product name providing recommendation supply ($CAD) Recommended daily usage  Type of product
Essiac 10 57.50±18.07 1 cup Herbal tea combination
Floressence 9 46.47±18.50 1 cup Herbal tea combination
Coenzyme Q10 4 34.24±6.12 100 mg/day Antioxidant
Ip6 (Inositol hexaphosphate) 4 60 12 caps/day Antioxidant
Moducare 4 45.99±18.38 As directed on bottle Sterols/sterolins
MGN 3 433.33±152.75 12 caps/day Mushroom extract
Pau D’arco 3 20 As directed on bottle Herb
Multivitamin 3 6.74±3.17 1 cap/day Vitamin
Ester-C 2 5.75 1 cap/day Vitamin
Pycnogelol 2 33.99 1 cap/day Antioxidant
Grape seed extract 2 43.50 1–3 caps/day Seed extract
Vitamin C 2 5 5000 mg/day Vitamin
Astragalus 2 14.99 As directed on bottle Herb
Greens+ 1 10.59 1 cup/day Herbal combination
Breast Health Combination 1 126.00 6–12 caps/day Herbal combination
Beta-carotene 1 2.00 10,000 mg/day Antioxidant
Shark Cartilage 1 104.00 8 caps/day Cartilage of shark
Cat’s claw 1 24.89 As directed on bottle Herb
RM-10 1 210.00 4–6 caps/day Mushroom and herbal
combination
Oregano oil 1 5.28 2 g/day Herbal extract
Proanthocyanidin 1 24.99 1–2 caps/day Antioxidant
Cancergo 1 69.00 2 caps t.i.d. Herbal combination
Collagen slim 1 69.00 15 ml q.i.d. Herbal combination
Mega B 1 9.66 1 cap/day Vitamin
Oncolyn 1 115.50 3 caps/day Botanical extract
Venus fly trap 1 N/A N/A Herb
Garlic 1 5.00 2–3 caps/day Botanical
Vitamin A 1 6.00 50,000 mg/day Vitamin
Vitamin E 1 6.00 400 IU/day Vitamin
Mushroom extract 1 24.99 As directed on bottle Mushroom extract
Maitake mushroom 1 75.00 As directed on bottle Mushroom extract
N/A, not applicable. ±, where shown, are standard deviations.who seek CAM might also be reinforced by dispensers of
CAM [28,29]. This was illustrated in our study by the
single employee who suggested that the patient discon-
tinue her chemotherapeutic drug (Tamoxifen) because it
was ‘poisonous’.
Many patients are attracted to NHP use because it is
natural, which is suggestive that this is less toxic than pre-
scription medication. Recent reports on adverse effects of
NHPs identify that several products once considered safe
might be harmful [5,10,30]. These risks are increased
when the products are used in large doses or chronically.
The heterogeneity of information about dosages increases
the likelihood for misuse. Recommendations such as
‘immune-boosting’ and ‘cleansing’ can be misleading to
patients as to the aetiology of their disease. The education
of employees about NHPs was also variable, with several
employees indicating that formal education was unneces-
sary. Others considered that working in the health food
environment for several years was experience enough.
Breast cancer patients are susceptible not only to adverse
health effects owing to advice and treatments provided by
natural health food stores but also to incurring significant
costs from purchasing natural health food products. The
monthly cost of products ranged from $5.28 (CAD) to
$600 (mean $58.09). The products that were most
expensive, such as the herbal teas and mushroom
extracts, rely on insufficient or questionable research and
evidence based on folklore.
Our study has some important limitations. The consistency
of data might be limited by approaching only one
employee at each store; however, we believe that this is
the closest to a real-life situation that can be replicated for
a study. It is difficult to measure employees’ knowledge of
cancer through a brief encounter, and the quality of infor-
mative literature varies substantially. It is possible that the
responses from employees varied according to each data
gatherer. It might be that gatherers presenting themselves
as breast cancer patients would have elicited different rec-
ommendations. Although this study was conducted in one
city in Canada, we believe that the results could be widely
transferable, because several of the stores were national
chains. All research assistants were trained and had fol-
lowed a structured questionnaire; they had completed the
questionnaire immediately after leaving the store, to avoid
inter-observer variation in collection and recall.
A potential concern to the conduct of this study relates to
its ethical implications. In essence, this was an investiga-
tion on human subjects without consent. Informed consent
is the cornerstone of research ethics [31]. However, there
are situations in which informed consent is not a neces-
sary precondition. This study might be such an exception:
first, there is little conceivable harm in not obtaining
consent in this particular setting; second, with informed
consent the investigation would not have been possible;
third, our aim was to investigate an area of potential harm
to consumers, which can be viewed as overriding con-
cerns about the potential of harm to shop assistants in this
setting. We therefore feel that, on balance, the study was
ethically justifiable, a judgement shared by the review
board that approved it.
Conclusion
Governing bodies should consider health food stores as
commonly used, yet unregulated, sections of the health
care system. Educational interventions aimed at employ-
ees might help to facilitate cooperation rather than stimu-
late antagonism [12]. Education about safety and drug
interactions as well as regulations about the extent of
advice might best help to coordinate a move towards a
safer and more evidence-based health food business.
Concerned physicians and regulating bodies should be
aware of the variety of advice that breast cancer patients
receive about NHP use. Discussions about efficacy, safety
and cost should be initiated to be consistent with the
health beliefs and expectations of the patients and
providers.
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